<DOC>
	<DOC>NCT02045589</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of three intratumoral injections of VCN-01 combined with Abraxane®/gemcitabine, and to determine the recommended phase II dose of VCN-01 combined with Abraxane®/gemcitabine.</brief_summary>
	<brief_title>A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Investigational treatment is a dose-escalation regimen consisting of three VCN-01 intratumoral injections (once every 28 days at the same dose) in combination with intravenous Abraxane® and gemcitabine.</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Male/Female patients aged 18 years or over Patients must provide written informed consent Life expectancy above 3 months Patients willing to comply with treatment followup, and to accept a biopsy at day 29 after initiation of the treatment Patients with histologically confirmed diagnosis of unresectable pancreatic adenocarcinoma with symptoms related to the primary tumor. Abraxane® plus Gemcitabine should be the appropriate standard of care to be administered. ECOG Performance status 0 or 1 Adequate baseline organ function (hematologic, liver, renal and nutritional) Use a reliable method of contraception in fertile men and women Active infection or other serious illness or autoimmune disease Treatment with live attenuated vaccines in the last three weeks Known chronic liver disease (liver cirrhosis, chronic hepatitis) Treatment with another investigational agent within its five halflives prior to VCN01 infusion Viral syndrome diagnosed during the two weeks before inclusion Chronic immunosuppressive therapy Known concurrent malignant hematologic or solid disease Pregnancy or lactation. Patients must agree to use effective contraception or be surgically sterile. Patients receiving fulldose anticoagulant / antiplatelet therapy Patients with Li Fraumeni syndrome or with previous known retinoblastoma protein pathway germinal deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Pancreatic adenocarcinoma</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Oncolytic virus</keyword>
	<keyword>Abraxane®</keyword>
</DOC>